Eli Lilly Stock Downgrade by Leadink Partners Amid Concerns Oral Oral LPG-1 Drug Trial Results | Lly Stock Price
Eli Lilly’s Stock FACED RENEWED Pressure AFTER LEFRINK PARTNERS DOWENGRAED THE PHARMACETICAL GIAnt, Citing Concerns Over The Company’s LPG-1 Drug Franchise-Particularly Following Underwhelming Trial Results for ITS Oral LPG-1 candidate, orforglipron. The